Clinical Briefings™: Treating Glaucoma with Rho Kinase Inhibition: Analyzing the Mechanism of Action and Latest Clinical Data
January 31, 2020
January 31, 2021
Scroll to the Bottom of this Information to Begin this Course
This activity is provided by Physicians’ Education Resource®, LLC.
Supported by an educational grant from Aerie Pharmaceuticals, Inc.
- Physicians — maximum of 1.0 AMA PRA Category 1 Credit(s)™
- Physicians’ Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 1 Contact Hours.
All other health care professionals completing this course will be issued a statement of participation.
This online educational activity is directed toward ophthalmologists and other healthcare professionals involved in treating glaucoma with ROCK inhibition.
Glaucoma is a heterogeneous group of diseases that has become a major cause of irreversible blindness worldwide. Current approaches for treating glaucoma are aimed at lowering intraocular pressure (IOP) but often require daily administration of multiple drops, leading to poor patient compliance. A new class of therapy, Rho-associated protein kinase (ROCK) inhibitors, offers a novel mechanism that targets the trabecular meshwork pathway to lower intraocular pressure at both higher and lower baseline levels and with day and night consistency.
This Clinical Briefings™ program features text content complemented by audio commentary from Janet B. Serle, MD, an expert in treating patients with glaucoma. Dr Serle will first describe the mechanism of action for ROCK inhibition and then review the safety and efficacy of single- and fixed-dose ROCK inhibitors from a series of clinical trials. Additional potential applications of ROCK inhibition will be explored, including treatment of other ophthalmic diseases and optic nerve protection.
Benefits of Participating
- Understand the effects of rho kinases in the trabecular meshwork that contribute to increased IOP
- Learn about the multiple mechanisms of ROCK inhibitors that reduce IOP
- Incorporate ROCK inhibitors into practice for your patients with glaucoma or ocular hypertension
- Gain awareness of future clinical applications of ROCK inhibitors in other ophthalmic diseases and conditions
Upon completion of this activity, you should be better prepared to:
- Discuss the rho-associated protein kinase pathway as a target for therapy to lower intraocular pressure
- Evaluate efficacy and safety data investigating the use of Rho kinase (ROCK) inhibitors in the treatment of patients with glaucoma
- Assess preclinical and clinical trial data evaluating the potential applications of ROCK inhibitors for the management of other ocular conditions
Janet B. Serle, MD
Professor Emeritus of Ophthalmology
Icahn School of Medicine at Mount Sinai
New York, NY
Physician Accreditation Statement
Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians
Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physicians’ Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 1.0 Contact Hours.
Disclosures of Conflicts of Interest
Janet B. Serle, MD
- Grant/Research Support: Aerie Pharmaceuticals, Inc
- Consultant/Adviser: Allergan, Bausch + Lomb Inc.
The staff of Physicians' Education Resource®, LLC, (PER®) have no relevant financial relationships with commercial interests to disclose.
Instructions for Participation and Credit
- You will need to log in to participate in the activity.
- Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review audio files/content until you finish the presentation.
- At the end of the activity, “Educational Content/Videos” will be available for your reference.
- In order to receive a CME certificate, you must complete the activity.
- Complete the Posttest and pass with a score of 70% or higher, complete the Evaluation, and then click on “Request for Credit.” You may immediately download a CME Certificate upon completion of these steps.
Course Viewing Requirements
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above.
Disclosure Policy and Resolution of Conflicts of Interest (COI)
As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME/CE activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME/CE activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that creates a COI.
Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process.
Disclosure of Unlabeled Use
This CME/CE activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME/CE activity is for continuing medical and nursing education purposes only and is not meant to substitute for the independent clinical judgment of a physician and nurse relative to diagnostic or treatment options for a specific patient’s medical condition.
The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or the company that provided commercial support.